Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.58 |
| ▸ | CCKBR | P32239 | 8/20 | 0.75 |
| ▸ | CCKAR | P32238 | 2/20 | 0.64 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | MMP14 | P50281 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22590113 | 0.99 | CCKBR (0.76) | CCKBRCCKARMMP2MMP9MMP8 | |
| SCHEMBL28318023 | 0.99 | CCKBR (0.76) | CCKBRCCKARMMP2MMP9MMP8 | |
| SCHEMBL184330 | 0.99 | CCKBR (0.76) | CCKBRCCKARMMP2MMP9MMP8 | |
| SCHEMBL11699855 | 0.93 | CCKBR (0.68) | CCKBRCCKARMMP2MMP9MMP8 | |
| SCHEMBL5384805 | 0.93 | CCKBR (0.66) | CCKBRMMP2MMP9MMP8MMP14 | |
| SCHEMBL11568613 | 0.90 | CCKBR (0.92) | CCKBRCCKAR | |
| SCHEMBL30999544 | 0.89 | CCKBR (0.74) | CCKBRCCKAR | |
| SCHEMBL30999586 | 0.89 | CCKBR (0.74) | CCKBRCCKAR | |
| SCHEMBL30999587 | 0.89 | CCKBR (0.74) | CCKBRCCKAR | |
| SCHEMBL30999592 | 0.89 | CCKBR (0.74) | CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048180-A1 | Sustained-release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-02-19 | — | — | US | disclosed |
| US-7048947-B2 | Sustained-release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-23 | — | — | US | disclosed |
| EP-1088555-B1 | Sustained-release leuprorelin preparation | TAKEDA PHARMACEUTICAL (JP) | 2005-05-18 | — | — | EP | disclosed |
| EP-1404516-A2 | MICROENCAPSULATION OF DRUGS BY SOLVENT EXCHANGE | PURDUE RESEARCH FOUNDATION (US) | 2004-04-07 | — | — | EP | disclosed |
| US-6599627-B2 | Based on exchange of water and a hydrophilic organic solvent whereby a decline in solvent quality for solvent causes a polymer dissolved therein to be deposited onto an aqueous core | PURDUE RESEARCH FOUNDATION | 2003-07-29 | — | — | US | disclosed |
| WO-2003053325-A2 | MICROENCAPSULATION OF DRUGS BY SOLVENT EXCHANGE | PURDUE RESEARCH FOUNDATION (US) | 2003-07-03 | — | — | WO | disclosed |
| EP-0058481-B2 | Continuous release pharmaceutical compositions | ASTRAZENECA AB (SE) | 2003-05-21 | — | — | EP | disclosed |
| US-6528093-B1 | Dissolving leuprorelin in an orgaic solvent of hydrocarbon halides, alkyl ethers or esters and aromatic hydrocarbons along with glycolic acid-lactic acid copolymer; adding a water mixture and desolventizing to form microcapsules | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-03-04 | — | — | US | disclosed |
| US-20030039698-A1 | SUSTAINED-RELEASE PREPARATION | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2003-02-27 | — | — | US | disclosed |
| US-20020173467-A1 | Sustained-release preparation | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2002-11-21 | — | — | US | disclosed |
| US-5854384-A | Process for preparing poly-α-amino acid particles | SR CORPORATION (JP) | 1998-12-29 | — | — | US | disclosed |
| US-5668111-A | POLYPEPTIDE HORMONE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-16 | — | — | US | disclosed |
| US-5480868-A | Sustained-release preparation | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-01-02 | — | — | US | disclosed |
| US-5366734-A | Implantable or injectable composition with polylactide or copolymer with glycolic acid with polypeptides for sustained release | ZENECA LIMITED (GB) | 1994-11-22 | — | — | US | disclosed |
| EP-0601799-A1 | Sustained-release preparation | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-06-15 | — | — | EP | disclosed |
| US-5100669-A | Controlled release drug delivery | BIOMATERIALS UNIVERSE, INC. (JP) | 1992-03-31 | — | — | US | disclosed |
| US-5004602-A | Containing Polypeptides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-04-02 | — | — | US | disclosed |
| US-4767628-A | POLYLACTONE AND ACID STABLE POLYPEPTIDE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-08-30 | — | — | US | disclosed |
| EP-0058481-B1 | CONTINUOUS RELEASE PHARMACEUTICAL COMPOSITIONS | ZENECA LIMITED (GB) | 1986-10-01 | — | — | EP | disclosed |
| EP-0058481-A1 | Continuous release pharmaceutical compositions | ZENECA LIMITED (GB) | 1982-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030039698-A1 | SUSTAINED-RELEASE PREPARATION | ARGLU1, NGLY1, NPR1 | MMP8 3457/4885CCKBR 125/4885CCKAR 194/4885 |
| US-20090048180-A1 | Sustained-release preparation | ARGLU1, NPR1, GHRHR | MMP8 3240/4885CCKBR 105/4885CCKAR 213/4885 |
| US-20020173467-A1 | Sustained-release preparation | ARGLU1, NGLY1, NPR1 | MMP8 3457/4885CCKBR 125/4885CCKAR 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.